{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"COMPEL","nct_id":"NCT04765059","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=compel-nct04765059. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"COMPEL","arms":[{"description":"All randomized patients will receive osimertinib 80 mg QD with pemetrexed (500 mg/m\\^2) (with pre-treatment) plus either cisplatin (75 mg/m\\^2) or carboplatin (\\[AUC\\] 5), both administered on Day 1 of 21-day cycles for 4 cycles, followed by osimertinib 80 mg QD plus pemetrexed maintenance (500 mg/m\\^2) on Day 1 of 21-day cycles","label":"Treatment Arm A","type":"EXPERIMENTAL"},{"description":"All randomized patients will receive placebo QD with pemetrexed (500 mg/m\\^2) (with pre-treatment) plus either cisplatin (75 mg/m\\^2) or carboplatin (AUC5), both administered on Day 1 of 21-day cycles for 4 cycles, followed by placebo QD plus pemetrexed maintenance (500 mg/m\\^2) on Day 1 of 21-day cycles","label":"Treatment Arm B","type":"PLACEBO_COMPARATOR"}],"collaborators":["Parexel"],"completion_date":{"date":"2027-06-02","type":"ESTIMATED"},"conditions":["Non-small Cell Lung Cancer"],"enrollment":{"count":98,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin","otherNames":[],"type":"DRUG"},{"name":"Placebo for osimertinib (AZD9291) pemetrexed cisplatin or carboplatin","otherNames":[],"type":"DRUG"}],"last_update":"2026-07-07","lead_sponsor":"AstraZeneca","official_title":"A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Platinum Plus Pemetrexed Chemotherapy Plus Osimertinib Versus Platinum Plus Pemetrexed Chemotherapy Plus Placebo in Patients With EGFRm, Locally Advanced or Metastatic NSCLC Who Have Progressed Extracranially Following First-Line Osimertinib Therapy (COMPEL)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2024-10-28","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression Free Survival (PFS)","timeFrame":"From date of first dose (Day 1) until date of progression at local site or death due to any cause or data cut-off date whichever occurred first (up to 3 years 1 month)"}],"references":[],"start_date":{"date":"2021-09-12","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)","url":"https://clinicaltrials.gov/study/NCT04765059"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/compel-nct04765059"}